{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:59:42Z","timestamp":1791118782782,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.cardfail.2012.02.005","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T09:09:09Z","timestamp":1333012149000},"page":"265-281","source":"Crossref","is-referenced-by-count":47,"title":["Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee"],"prefix":"10.1016","volume":"18","author":[{"given":"Javed","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Givertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary N.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Westlake Canary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Colvin-Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray E.","family":"Hershberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy K.","family":"Sweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"Wilson Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Gattis","family":"Stough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2012.02.005_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2012.02.005_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study nvestigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib3","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib5","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/01.CIR.0000091234.45664.62","article-title":"Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial","volume":"108","author":"Cohn","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib9","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib12","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI103022","article-title":"Observations on the sodium-retaining corticoid (aldosterone) in the urine of children and adults in relation to sodium balance and edema","volume":"33","author":"Luetscher","year":"1954","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cardfail.2012.02.005_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI103470","article-title":"Increased aldosterone secretion in dogs with right-sided congestive heart failure and in dogs with thoracic inferior vena cava constriction","volume":"36","author":"Davis","year":"1957","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cardfail.2012.02.005_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","article-title":"Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators","volume":"100","author":"McKelvie","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib15","doi-asserted-by":"crossref","first-page":"40D","DOI":"10.1016\/0002-9149(90)90475-G","article-title":"Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group","volume":"66","author":"Swedberg","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMe030030","article-title":"Aldosterone blockade and heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","article-title":"Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure","volume":"93","author":"Qin","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2012.02.005_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncpneph0362","article-title":"Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade","volume":"3","author":"Del Vecchio","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/en.2010-0925","article-title":"11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-\/- mice","volume":"152","author":"Deuchar","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.cardfail.2012.02.005_bib22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/hrt.2003.017368","article-title":"Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment","volume":"90","author":"Macdonald","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2012.02.005_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","article-title":"Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients","volume":"35","author":"MacFadyen","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2012.02.005_bib24","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib25","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1172\/JCI36908","article-title":"The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice","volume":"119","author":"Gumz","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cardfail.2012.02.005_bib26","doi-asserted-by":"crossref","first-page":"F1323","DOI":"10.1152\/ajprenal.90428.2008","article-title":"Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation","volume":"296","author":"Huang","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib27","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions","volume":"297","author":"Lee","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in\u00a0vivo and in\u00a0vitro","volume":"240","author":"de","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cardfail.2012.02.005_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2012.02.005_bib36","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1463-1326.2007.00730.x","article-title":"Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS","volume":"10","author":"O'Keefe","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cardfail.2012.02.005_bib37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2012.02.005_bib38","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib39","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.cardfail.2008.07.189","article-title":"Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial","volume":"14","author":"Ghali","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2012.02.005_bib40","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib41","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cardfail.2012.02.005_bib43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14740338.1.3.207","article-title":"Controversy surrounding the safety of cerivastatin","volume":"1","author":"Davidson","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cardfail.2012.02.005_bib44","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1001\/jama.298.22.2634","article-title":"Thiazolidinediones and cardiovascular outcomes in older patients with diabetes","volume":"298","author":"Lipscombe","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2012.02.005_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ahj.2006.11.008","article-title":"A population-based analysis of the class effect of beta-blockers after myocardial infarction","volume":"153","author":"Rinfret","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib46","unstructured":"http:\/\/www.pharmacychecker.com\/strength.asp?drugid=19309. Accessed March 20,\u00a02011."},{"key":"10.1016\/j.cardfail.2012.02.005_bib47","unstructured":"http:\/\/i.walmartimages.com\/i\/if\/hmp\/fusion\/customer_list.pdf. Accessed March 20,\u00a02011."},{"key":"10.1016\/j.cardfail.2012.02.005_bib48","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib49","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2012.02.005_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.30.1.1","article-title":"Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure","volume":"30","author":"Cavallari","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cardfail.2012.02.005_bib51","doi-asserted-by":"crossref","first-page":"c1768","DOI":"10.1136\/bmj.c1768","article-title":"Spironolactone use and renal toxicity: population based longitudinal analysis","volume":"340","author":"Wei","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cardfail.2012.02.005_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjcard.2004.04.059","article-title":"Usefulness of spironolactone in a specialized heart failure clinic","volume":"94","author":"Sligl","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib54","unstructured":"G.D.Searle LLC, division of Pfizer Inc. Inspra (eplerenone) package insert.\u00a02008."},{"key":"10.1016\/j.cardfail.2012.02.005_bib55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00498250310001649341","article-title":"Prediction of in\u00a0vivo drug interactions with eplerenone in man from in\u00a0vitro metabolic inhibition data","volume":"34","author":"Cook","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.cardfail.2012.02.005_bib56","unstructured":"Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine http:\/\/medicine iupui edu\/clinpharm\/ddis\/table asp. Accessed January 23,\u00a02012."},{"key":"10.1016\/j.cardfail.2012.02.005_bib57","unstructured":"Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.http:\/\/cp gm com. Accessed March 17,\u00a02011."},{"key":"10.1016\/j.cardfail.2012.02.005_bib58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/dmd.32.6.581","article-title":"Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity","volume":"32","author":"Hidaka","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cardfail.2012.02.005_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1081\/DMR-120001389","article-title":"Drugs as P-glycoprotein substrates, inhibitors, and inducers","volume":"34","author":"Kim","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.cardfail.2012.02.005_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-198815040-00003","article-title":"Pharmacokinetic interactions with digoxin","volume":"15","author":"Rodin","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cardfail.2012.02.005_bib61","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community","volume":"296","author":"Bursi","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2012.02.005_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/01.CIR.56.2.273","article-title":"Echocardiographic assessment of a normal adult aging population","volume":"56","author":"Gerstenblith","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cpcardiol.2008.10.002","article-title":"Aldosterone and cardiovascular disease","volume":"34","author":"Gaddam","year":"2009","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11906-000-0041-z","article-title":"The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure","volume":"2","author":"Hameedi","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cardfail.2012.02.005_bib66","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"Mak","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib67","unstructured":"National Heart Lung and Blood Institute. Aldosterone Antagonist Therapy for Adults with Heart Failure and Preserved Systolic Function (TOPCAT), NCT00094302. http:\/\/www.clinicaltrials.gov. 10-6-2009. 3-1-2011. Accessed March 1, 2011."},{"key":"10.1016\/j.cardfail.2012.02.005_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib69","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib70","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators","volume":"335","author":"Moss","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib71","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2012.02.005_bib73","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2012.02.005_bib74","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.echo.2010.01.017","article-title":"Visual assessment of left ventricular function in the era of high definition: the machine and the eye of the beholder","volume":"23","author":"Kalogeropoulos","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cardfail.2012.02.005_bib76","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart disease and stroke statistics\u20132011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib77","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the united states: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib78","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0002-9149(01)01460-6","article-title":"M-mode echocardiographic predictors of six-\u00a0to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study)","volume":"87","author":"Gardin","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib79","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0735-1097(01)01110-X","article-title":"Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study","volume":"37","author":"Aurigemma","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib80","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/oxfordjournals.aje.a009406","article-title":"All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study","volume":"147","author":"Lee","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(97)03033-X","article-title":"Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population","volume":"350","author":"McDonagh","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2012.02.005_bib82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/euhj.1998.1239","article-title":"Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study","volume":"20","author":"Mosterd","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib83","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2012.02.005_bib84","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2012.02.005_bib85","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart\u00a0failure stages: application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2012.02.005_bib86","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.jacc.2004.01.041","article-title":"Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge","volume":"43","author":"Butler","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib87","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jacc.2006.03.030","article-title":"Beta-blocker use and outcomes among hospitalized heart failure patients","volume":"47","author":"Butler","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib88","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0002-9149(02)03104-1","article-title":"Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure","volume":"91","author":"Gattis","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib89","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jacc.2003.12.040","article-title":"Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial","volume":"43","author":"Gattis","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2003.08.012","article-title":"Relationship between heart failure treatment and development of worsening renal function among hospitalized patients","volume":"147","author":"Butler","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2012.02.005_bib91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","article-title":"Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure","volume":"43","author":"Forman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib92","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cardfail.2011.03.005","article-title":"Heart failure with recovered ejection fraction: a distinct clinical entity","volume":"17","author":"Punnoose","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2012.02.005_bib93","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2011.05.033","article-title":"Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study","volume":"58","author":"McNamara","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2012.02.005_bib94","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/eurjhf\/hfq049","article-title":"Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)","volume":"12","author":"Zannad","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2012.02.005_bib95","doi-asserted-by":"crossref","first-page":"d5228","DOI":"10.1136\/bmj.d5228","article-title":"Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study","volume":"343","author":"Antoniou","year":"2011","journal-title":"BMJ"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916412000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916412000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T09:16:24Z","timestamp":1742807784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916412000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1071916412000760"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2012.02.005","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}